生物活性
CUDC-101是一种抑制多种靶标的新型化合物，旨在抑制HDAC，EGFR和Her2。
Targets
| Target | Value |
| EGFR | IC50: 2.4nM |
| HDAC | IC50: 4.4nM |
| HDAC1 | IC50: 4.5nM |
| HDAC6 | IC50: 5.1nM |
| HDAC3 | IC50: 9.1nM |
| HDAC5 | IC50: 11.4nM |
| HDAC2 | IC50: 12.6nM |
| HDAC4 | IC50: 13.2nM |
| HER2 | IC50: 15.7nM |
| HDAC10 | IC50: 26.1nM |
| HDAC9 | IC50: 67.2nM |
| HDAC8 | IC50: 79.8nM |
| HDAC7 | IC50: 373nM |
化学数据
| 目录号 | A10246 |
| 作用机制 | Inhibitor (抑制剂) |
| M. Wt | 434.5 |
| Formula | C24H26N4O4 |
| Purity | >99% |
| Storage | Store lyophilized at -20ºC, keep desiccated.
In lyophilized form, the chemical is stable for36 months.
In solution, store at -20ºC and use within3 monthsto prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. |
| CAS No. | 1012054-59-9 |
| Synonyms | CUDC101 |
| SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCCCCC(=O)NO |
溶解度
| In vitro (25°C) | DMSO | 20 mg/mL (46.03 mM) |
| Water | Insoluble |
| Ethanol | Insoluble |
| In vivo | 15% Captisol | 28 mg/mL |
*<1 mg/ml means slightly soluble or insoluble.
*Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
储备液配制
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
| 0.1 mM | 23.01 mL | 115.07 mL | 230.15 mL |
| 0.5 mM | 4.6 mL | 23.01 mL | 46.03 mL |
| 1 mM | 2.3 mL | 11.51 mL | 23.01 mL |
| 5 mM | 0.46 mL | 2.3 mL | 4.6 mL |
*The above data is based on the productmolecular weight 434.5 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
m.cnreagent.com